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Under common practice, recognition and treatment of type 2 diabetic nephropathy (DN) are usually revealed at a rather
late stage (CKD stages 3–5) due to the insensitiveness of available diagnostic markers. Accumulating data obtained from
vascular homeostasis in late stage DN demonstrated (1) a defective angiogenesis and impaired NO production which explains
the therapeutic resistance to vasodilators and the inability to correct chronic renal ischemia and (2) an abnormally elevated
antiangiogenesis and a progressive vascular disease which correlates with the altered renal hemodynamics characterized by a
progressive reduction in renal perfusion as the disease severity progressed. In contract, the vascular homeostasis is adequately
functional in early stage DN. Thus, vasodilator treatment at early stage DN (CKD stages 1-2) can enhance renal perfusion, correct
the renal ischemia, and restore renal function.
1.ProblemsRelevantto Present
TherapeuticFailure in Diabetic Nephropathy
underCurrentPractice
Under current practice, determinations of serum creatinine
and microalbuminuria are used to screen for diabetic
nephropathy (DN), which is reﬂected by microalbuminuria
(30–300 milligrams of urinary albumin/gram creatinine, or
greater) and serum creatinine concentration greater than
1mg/dL. In accordance with the 5 stages of chronic kidney
disease (CKD), serum creatinine usually does not change
at the early stage (CKD stages 1-2; creatinine clearance
60–119mL/min/1.73m2), but becomes abnormally elevated
only when the creatinine clearance drops to the level
of ﬁfty percent (CKD stages 3–5; creatinine clearance
<60mL/min/1.73m2). Similarly, microalbuminuria is usu-
ally detected when the creatinine clearance is approaching
ﬁfty percent level as depicted in Figure 1 [1, 2]. This implies
that under current practice, these diagnostic markers do not
recognize diabetic patient at the early stage and we allow
these patients to progress towards late stage of CKD without
any therapeutic intervention. In contrast to this current
practice, new diagnostic markers such as (1) measured
creatinine clearance would recognize all stages of CKD and
(2) FE Mg, which has previously been demonstrated to
correlate directly with the magnitude of tubulointerstitial
ﬁbrosis, would recognize early stage of CKD with a mildly
impaired renal function [3]. Enhanced excretion of urinary
magnesium resulting in abnormal FE Mg is due to the
increased detachment of magnesium attached to the ATPase
enzymes in the tubular cell following the tubulointersti-tial
disease. Therefore, these new diagnostic markers assist to
diﬀerentiate the diabetic patients at the early stage (nor-
moalbuminuria) from the normal population. We have
recently demonstrated that diabetic patients in this stage
of normoalbuminuria have values of serum creatinine,
and urinary microalbumin/creatinine ratio not signiﬁcantly
diﬀerent from the normal controls. (Table 1)H o w e v e r ,t h e s e
diabetic patients would be easily recognized by (1) measured
creatinine clearance which is signiﬁcantly impaired, (2) FE
Mg value doubling the value of normal control, which
reﬂects the presence of tubulointerstitial ﬁbrosis, and (3)
evidenceofrenal ischemia which isreﬂectedbythereduction
in peritubular capillary ﬂow.2 International Journal of Vascular Medicine
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Figure 1: Comparison between conventional and newdiagnostic
markers.
Table 1: Clinical ﬁndings in early stage of type 2 DN (normoalbu-
minuria).
Pretreatment Normal P value
Renal function
SC rm g / d L 0 . 9± 0.5 <1 <.05
MA/Cr μg/mg 13 ± 5 <30 NS
CCr ml/min/1.73m2 84 ± 24 <120 <.01
FE Mg 3.5 ± 1.3 <2.2 <.05
Hemodynamics
Futrakul (2007)
PTCF mL/min/1.73m2 292 ± 41 485 ± 39 <.01
GFR mL/min/1.73m2 88 ± 28 119 ± 15 <.001
The insensitiveness of the available diagnostic markers is
responsible for the present therapeutic failure in restoring
renal perfusion and function. Vasodilators treatment initi-
ated at the late stage of DN is characterized by therapeutic
ineﬀectiveness.Inthisregard, we haverecentlydemonstrated
that such therapeutic failure correlates with the progressive
reduction in peritubular capillary ﬂow. This would raise an
interesting questionas towhether what would be responsible
for such therapeutic unresponsiveness to vasodilators in late
stage of DN.
2.VascularHomeostasisinNormal
(Physiologic) and Diabetes(Pathologic)
Normalvascular homeostasis is thebalance between vascular
injury and vascular repair. Vascular injury is usually induced
by circulating triggers such as altered shear stress [4, 5],
oxidative stress [6], cytokine [7], and angiotensin I (AII)
[8]. It is reﬂected by endothelial cell loss from the vascular
wall into the circulation, the so-called circulating endothelial
cell. This circulating endothelial cell is associated with
receptor-bound VEGF as suggested by Hohenstein [9]. We,
therefore, have studied circulating endothelial cell-receptor-
bound VEGF in normal controls and diabetic patients. With
respect to VEGF receptors, there is much debate about
t h e i ra c t i v er o l e s( V E G F R 1 ,V E G F R 2 )w h e t h e rw h i c hV E G F
receptor plays the pathologic role in the progression of renal
microvasculardiseaseindiabetes.Inanswering thisquestion,
we have compared the change in renal hemodynamics which
is reﬂected by the reduction in peritubular capillary ﬂow,
with the change in VEGF receptors, to explain the renal
microvascular disease progression. During the early stage
of DN (normoalbuminuria), there is evidence of renal mi-
crovascular disease which is reﬂected by the reduction in
peritubular capillary ﬂow. However, the vascular homeosta-
sis in this stage reﬂected by both VEGFR1 and VEGFR2
is not signiﬁcantly diﬀerent from the control, indicating a
fairly compensatory status of vascular repair, despite the
presence of a mild degree of renal ischemia as depicted in
Table 2. During the late stage of DN, there is a progression of
renal microvascular disease which is reﬂected by the further
reduction in peritubular capillary ﬂow. This hemodynam-
ic change correlates with the defective VEGFR1 and the
abnormally elevated level of VEGFR2. Such changes imply
that the predominant role of VEGFR2 determines the
progression of renal microvascular disease, and, therefore,
VEGFR2isconsideredtobeantiangiogenicwhereasVEGFR1
is angiogenic.
3.VascularHomeostasisunder
Physiologic Condition
The study of vascular homeostasis in the controls reveals
normal values of both angiogenic factors, namely, VEGF,
VEGFR1, endothelial progenitor cell, and angiopoietin 1,
and antiangiogenic factors, namely, VEGFR2 and angiopoi-
etin 2. In response to vascular injury under physiologic con-
dition, both VEGFR1 and VEGFR2 are essential in coordi-
nating endothelial cell assembly [10]. Vascular repair would
recruit (I) VEGF to activate through VEGFR1, whereas
activation through VEGFR2 is physiologically suppressed
due to the high aﬃnity of VEGFR1. This would physiolog-
ically induce Akt phosphorylation, coupling of endothelial
nitric oxide synthase (eNOS), and enhance NO production.
Previous studies showed that (i) short-term activation of
endothelial Akt phosphorylation leads to increased NO pro-
duction, re-endothelialization, angiogenesis, and vascular
protection[11]. (ii) VEGF to activate eNOS via VEGFR1 and
that the NO produced then negatively regulates endothelial
cell proliferation by VEGFR2 while promoting endothelial
cell tubular formation and diﬀerentiation into capillary
networks [12, 13]. (II) endothelial progenitor cell to the site
of vascular injury and angiopoietin 1 in conjunction with
the enhanced NO production to corporate in physiologic
stimulation of endothelial cell proliferation and maturation.
Previous studies demonstrated that exogenous recombinant
angiopoietin 1 enhances the growth of interstitial capillaries
in mouse metanephric organ culture [14], and the factor
enhances transendothelial electrical resistance in monolayer
cultures of glomerular endothelial cell [15]. Collectively,
all these factors integrate in ﬁne-tuning the angiogenic
response to vascular endothelial growth factor, resultingInternational Journal of Vascular Medicine 3
Table 2: A predominant role of VEGFR2 correlates with PTCF reduction in late stage of DN.
Vascular homeostasis Renal hemodynamics
Early DN P value Normal Early DN P value Normal
VEGF R1 ng/mL 60±12 NS 49 ± 5 PTCF mL/min/1.73m2 379 ± 70 <.05 483 ± 43
VEGF R2 ng/mL 5715 ± 1400 NS 6126 ± 1066
Late DN P value Normal Late DN P value Normal
VEGF R1 ng/mL 33 ± 17 <.01 55 ± 11 PTCF mL/min/1.73m2 277 ± 80 <.001 483 ± 43
VEGF R2 ng/mL 10414 ± 2198 <.01 7696 ± 1892
Circulating triggers
Shear stress, cytokines, oxidative stress, lipid
Physiologic vascular homeostasis
Vascular injury
Circulating endothelial cells
Vascular repair VEGF VEGFR1 VEGFR2 EPC,
angiopoietin 1
Akt phosphorylation
eNOS
NO production
Physiologic EC proliferation,
maturation
Angiogenesis,
vascular repair
Figure 2: Vascular homeostasisunder physiologic condition.
in an adequate vascular repair and normal angiogenesis
(Figure 2).
4.PathologicVascularHomeostasisin
LateStageofDN
In diabetes, vascular injury is induced by a variety of cir-
culating toxins, namely, high glucose [15], oxidative stress
[6], cytokines [7], altered shear stress [4, 5], thrombin [16],
and angiotensin II (Ang II) [8]. Alteredvascular homeostasis
observedinlatestageofDNischaracterizedbybothdefective
angiogenicfactors, namely,VEGF,VEGFR1,endothelialpro-
genitor cells, and angiopoietin 1, as well as abnormally
elevated antiangiogenic factors, namely, VEGFR2 and angi-
opoietin 2 [17]. Such changes would incriminate in mixed
pictures of an insuﬃcient, physiologic vasculogenesis, and
of a pathologic progression of vascular disease resulting in
a progressive reduction in vascular perfusion to the kidney
as follows (Figure 3).
(I) With respect to VEGF, we have studied VEGF value
in the serum, which partly reﬂects a component of circu-
lating endothelial cell-receptor-bound VEGF detached from
the diseased vascular wall into the circulation. Our study
demonstrated a wide range of VEGF values with the mean
value of VEGF not signiﬁcantly diﬀerent from the control.
This observationofVEGFindiabeticpatientisquitecontrast
to the reduced VEGF value observed in the nondiabetic
chronic kidney disease patient [18]. Furthermore, several
reports on changes in VEGF gene expression in kidney
tissue are interesting. Bortolosa et al. [19]d e m o n s t r a t e da
signiﬁcant inverse correlation between total intraglomerular
VEGF in RNA level and albumin excretion rate. Both the
degree of mesangium and mesangial matrix expansion were
inversely related to VEGF 165 and directly related to VEGF
121 in RNA levels. In addition, a strong inverse correlation
between VEGF 165 and VEGF 121 isoforms was also found.
Hohenstein et al. [9] demonstrated that VEGF expression
was increased in all diabetic glomeruli by many diﬀerent
cell types. In contrast, VEGF receptor activation or receptor-
bound VEGF was increased predominantly in the endothe-
lium of only mildly injured glomeruli but not severe diabetic
lesions. Cooper et al. [20] suggested that although VEGF-A
may be elevated in the initial phase of diabetic nephropathy,
it may not be maintained as more chronic ﬁbrotic changes
occur in the kidney. Indeed, in many animal models of
chronic kidney disease, VEGF-A levels are reduced, correlat-
ing with the progression of renal damage [21, 22]. The dif-
ferent expressions of VEGF gene in diﬀerent stages of DN is,
therefore, dependent upon the dynamic balance between the
degree of vascular injury and the stage of disease resulting in
the detachment of receptor-bound VEGF from the diseased
vascular wall into the circulation, and the ability to maintain
thevascularrepairbyreleasing theVEGF fromtheremaining
sources such as podocyte, tubularcell, pericyte, and so forth.
(II) With respect to defective VEGFR1 documented in
thisstudyinlatestageofDN,theactivationofVEGFthrough
the classical VEGF → VEGFR 1 pathway would be defective,
impairs physiologic Akt phosphorylation, uncoupling of
eNOS,andthusimpairsNOproduction.Previousstudycon-
ﬁrmed this view in vitro when VEGFR 1 was knocked down
in endothelial cells using retroviral small interfering RNAfor
VEGFR 1, but not VEGFR 2; the cGMP was lower in VEGFR
1 knockeddownendothelialcells, suggesting a decreasedNO
bioavailability [23].
(III) With respect to the defective endothelial progenitor
cell and angiopoietin 1, diabetic patients have been reported
to have a reduced number of circulating endothelial progen-
itor cell as well as its function, with the extent of reduction
directly proportional to plasma hemoglobin A1C level [24,
25]. A defective endothelial progenitor cell in conjunc-
tion with an impaired NO production would impair the
physiologic stimulation of endothelial cell proliferation and4 International Journal of Vascular Medicine
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Figure 3: Pathologic vascular homeostasisin late stage of DN.
thus inadequately replace for the endothelial cell loss during
vascular injury. The defective angiopoietin 1 would also
impair the maturation and the maintenance of the integrity
ofthematurevessels.Previousstudydemonstratedareduced
angiopoietin 1 at 8 weeks following streptozotocin injection
in adult rats [26]. In addition, the increased expression of
antiangiogenic factor angiopoietin 2, triggered by high sugar
and angiotensin II, would further suppress the angiopoietin
1, then destabilize glomerular endothelium, and induce
endothelial apoptosis[15, 27, 28]. In human and animal dia-
betic nephropathy, increased angiopoietin 2 expression was
also observed by several investigators, namely, Rizkalla et al.
[26],Yamamoto et al.[29],andWoolfetal.[30].Collectively,
these would incriminate the impaired physiologic vascular
repair and induce insuﬃcient vasculogenesis. This ﬁnding
correlates well with the altered renal hemodynamic study,
which revealsa progressive reductionin peritubularcapillary
ﬂow in late stage of DN [2], a persistency of chronic ischemic
state of the tubulointerstitial structure, and a reduction in
peritubular capillary densities shown by platelet-endothelial
cell adhesion molecule-1/CD 31 staining [31]. In contrast
to the defective activation through the angiogenic VEGFR1
pathwayinlate stage ofDNabove, theactivation throughthe
antiangiogenic VEGFR2 pathway is excessively exaggerated
as follows.
(IV) With respect to the abnormally elevated antiangio-
genic VEGFR2 observed in late stage of DN, other studies
showed conﬂicting results. Cooper et al. [20]d e m o n s t r a t e d
that VEGFR2 was elevated in short-term diabetes, whereas
VEGFR2 was unaltered in long-term diabetic animals. How-
ever, Sasso et al. [32] demonstrated a reduction of both
V E G F R 1a n dV E G F R 2e x p r e s s i o n sa sw e l la sar e d u c t i o n
of VEGFR2 phosphorylation in the myocardium of diabetic
patients compared with nondiabetic patients. To explain
suchdiscrepancy,theobservationin thecardiac myocardium
may (i) not reﬂect the actual change of vascular homeosta-
sis occurring in the diseased coronary vessel, but simply
reﬂect the change in the underlying diseased myocardium
under the environment associated with a defective collateral
microcirculation in the heart and (ii) reﬂect the advanced
ischemic disease in myocardium which is similar to the
change observed in advanced stage of chronic ischemic renal
disease. In this regard, increased microvascular rarefaction
in the advanced disease of myocardium is similar to the
peritubular capillary rarefaction observed in the advanced
stage of tubulointerstitial ﬁbrosis in chronic kidney disease
[31, 33]. Under such advanced stage, there has been a
continuous process of vascular injury associated with a
progressive loss of endothelial cell-receptor-bound VEGF
attached to the diseased vessel into the systemic circulation.
In accordance with the increased VEGFR2 observed
in late stage of DN, it would pathologically activate Akt
phosphorylation through the NO-independent pathway to
induce endothelial cell proliferation and endothelial cell
dysfunction. Previous study demonstrated that this exces-
sive Akt activation under an impaired NO production
would instigate the angiogenic response to VEGF, negatively
regulat endothelial cell lifespan and inhibiting endothelial
tubular formation via a p53/p21-dependent pathway [11].
In the presence of the defective angiopoietin 1 inducing
an immature endothelial cell proliferation, in conjunction
with the elevated angiopoietin 2 destabilizing the endothe-
lial cell and enhancing endothelial apoptosis, these would
collectively induce an abnormally immature endothelial
cell proliferation. This cell would be consistent with the
endothelial-myoﬁbroblast transition cell as proposed by Li
and Bertram [34]. To explain the vascular smooth muscle
cell(VSMC)proliferation,theupregulationsofvasoconstric-
tor (angiotensin II), procoagulant proteins, cytokines, and
adhesion molecules in conjunction with the intraglomeru-
lar hypertension secondary to glomerular endothelial cell
dysfunction have been documented in a variety of chronic
kidney diseases and DN [5, 35]. Angiotensin II activates
NADPHoxidase,inducesreactiveoxygenspeciesandNK-πB
activation, then activates ERK-p38, JAK-STAT, and therefore
inducesVSMCproliferation.Moreover,theincreaseintrans-
muralpressureassociatedwithintraglomerularhypertension
would, in accordance with La Place’s law, translate into an
increase in biaxial tensile stress which then transmit into the
wall ofarteriole and enhance further the VSMC proliferationInternational Journal of Vascular Medicine 5
in the vascular wall. The VSMC proliferation would induce
a thickening of vascular wall, a narrowing of vascular
lumen, and eventually a progressive reduction in peritubular
capillary ﬂow. Collectively, these would incriminate in the
pathologic development of neoangiogenesis, a progressive
macro- microvascular disease. In this regard, Osterby and
Nyberg [36] described abnormal blood vessels in glomeruli
of patients with long-term type 1 diabetic, as well as type 2
diabeticpatients[37].MinandYamanaka [38]demonstrated
through analyses of computer-generated three-dimensional
images in 94 diabetic nephropathic patients and found
abnormal vessels anastomosed to the lobular structure of
the intraglomerular capillary network, mainly to aﬀerent
branches, while the distal end of the vessels connected to
the peritubular capillary. In these vessels, native endothelial
cell function was likely impaired, with the endothelial
cells initially swollen and endothelial thickness gradually
decreasing as diabetes progressed [39, 40].
(V) With respect to altered vascular homeostasis and
angiogenesis in diabetic retinopathy, expressions of VEGFA,
VEGFR1, and VEGFR2 were all increased in the retina of
diabetic or insulin-resistant rats [41]. Such change mimics
the altered vascular homeostasis observed in early or mildly
injured glomeruli. It is likely that in this circumstance of
elevated VEGFR2, the VEGFR1 activity would be unable
to suppress the VEGFR2. Therefore, the enhanced VEGF2
activity would pathologically stimulate Akt phosphorylation
through the NO-independent pathway (uncoupling eNOS),
and induce pathologic proliferation of abnormal, immature
endothelial cell. Mice with homozygous mutations that
inactivate either receptor (VEGFR1 or VEGFR2) die in utero
with a similar phenotype as mice with VEGF deletion,
indicating that both receptors are obligatory for the function
of VEGF [42, 43]. Althoughthe vascular phenotype between
these VEGFR mutant mice are overlapping to some degree,
they do diﬀer in terms of showing that VEGFR2, may play a
greater role in (pathologic) vascular organization [44]. Scott
McLeod demonstrated a strong expression of KDR/Flk1 by
proliferating endothelial cells in reforming retinal vessels
and intravitreal neovascularization after hyperoxic insult in
dog. Anti-KDR antibody delivered by slow-release pellets
had no eﬀect on normal vasculogenesis, but it inhibited
the formation of intravitreal neovascularization and retinal
vessel development in oxygen-induced retinopathy [45].
5.VascularHomeostasisinEarlyStageof
DN andTherapeuticImplication
In contrast to the abnormal vascular homeostasis and angio-
genesisobserved inlate stage ofDN,our study demonstrated
the values of vascular homeostasis observed in early stage
of DN (normoalbuminuria) not signiﬁcantly diﬀerent from
the control population [46]. This implies that this normal
vascular homeostasis would reﬂect an adequate function of
vascular repair. Theoretically, it would adequately induce the
Akt phosphorylation, coupling of eNOS, and thus enhance
NO production. Enhanced NO production would allow
a normal response to vasodilators treatment resulting in
vasodilating the underlying renal vasculature and restoring
renal perfusion. Indeed, increment in peritubular capillary
ﬂow is documented following vasodilators treatment in early
stage of DN during the stage of normoalbuminuria [47, 48].
Increased peritubular capillary ﬂow following the relaxation
of eﬀerent arteriole not only inhibits the mechanism of tub-
ulointerstitial ﬁbrosis, but also induces renal regeneration.
This is reﬂected by the regression of FE Mg following treat-
ment with vasodilators, since FEMgvaluecorrelateswith the
magnitude of tubulointerstitial ﬁbrosis. Simultaneously, it
also increases glomerular ﬁltration rate following the relaxa-
tion of aﬀerent arteriole.
In conclusion, the preceding information renders sup-
port that implementation of treatment at the early stage of
DN under the environment favorable for renal angiogenesis
and regenerationwouldeﬀectivelyrestore renal function and
prevent the end-stage renal disease.
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